<DOC>
	<DOCNO>NCT00831675</DOCNO>
	<brief_summary>To describe safety 2004-2005 pediatric formulation inactivate , split-virion influenza vaccine Fluzone® , give two-dose schedule accordance Package Insert , child age ≥ 6 month &lt; 36 month . To describe immunogenicity 2004-2005 inactivated , split-virion influenza vaccine Fluzone® , administer two-dose schedule accordance Package Insert , child age ≥ 6 month &lt; 36 month</brief_summary>
	<brief_title>Study Safety Immunogenicity Fluzone® Healthy Children</brief_title>
	<detailed_description>To provide Centers Biologic Evaluation Research ( CBER ) serum collect healthy child receive 2004-2005 formulation inactivate , split-virion influenza vaccine Fluzone® study Food Drug Administration ( FDA ) , Centers Disease Control Prevention ( CDC ) , World Health Organization ( WHO ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Participant age ≥ 6 month &lt; 36 month . Participant consider good health basis report medical history limited physical examination . Participant available duration study . Parent/guardian willing able provide inform consent . Parent/guardian willing able meet protocol requirement . Exclusion Criteria : Reported allergy egg protein , chicken protein , constituent vaccine . Previous history influenza vaccination document history influenza infection . An acute illness without fever ( temperature &gt; 100.4 °F rectal ) 72 hour precede enrollment trial ( defer enrollment ) . Clinically significant finding vital sign review system ( investigator judgment ; defer exclude ) . Participation clinical trial within 30 day prior enrollment termination subject 's participation study . Known suspect impairment immunologic function , receipt immunosuppressive therapy immunoglobulin since birth . Personal immediate family history congenital immune deficiency . Developmental delay , neurologic disorder , seizure disorder . Chronic medical , congenital , developmental disorder . Known human immunodeficiency virus ( HIV ) positive mother . Prior history GuillainBarré syndrome . Any condition , opinion investigator , would pose health risk subject interfere evaluation vaccine . Any vaccination 14 day precede enrollment study schedule Visit 1 Visit 3 .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Fluzone® vaccine</keyword>
	<keyword>Infants</keyword>
	<keyword>Toddlers</keyword>
</DOC>